These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

452 related articles for article (PubMed ID: 18057657)

  • 1. [Parathyroid and bone. Management of parathyroid function and evaluation of bone metabolism in hemodialysis patients].
    Goto S; Fukagawa M
    Clin Calcium; 2007 Dec; 17(12):1830-4. PubMed ID: 18057657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mineral and bone disorders in patients on dialysis: physiology and clinical consequences.
    McCarley PB; Arjomand M
    Nephrol Nurs J; 2008; 35(1):59-64. PubMed ID: 18372764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The course of osteodystrophy in patients with chronic kidney failure on hemodialysis].
    Zemchenko AIu; Shostka GD
    Urol Nefrol (Mosk); 1993; (6):51-4. PubMed ID: 8160326
    [No Abstract]   [Full Text] [Related]  

  • 4. [Kidney and bone update : the 5-year history and future of CKD-MBD. Bone metabolic marker in hemodialysis patients update].
    Okuno S
    Clin Calcium; 2012 Jul; 22(7):1009-17. PubMed ID: 22750933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO).
    Moe S; Drüeke T; Cunningham J; Goodman W; Martin K; Olgaard K; Ott S; Sprague S; Lameire N; Eknoyan G;
    Kidney Int; 2006 Jun; 69(11):1945-53. PubMed ID: 16641930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal osteodystrophy.
    Haas M
    Wien Med Wochenschr; 2004; 154(5-6):107-18. PubMed ID: 15106893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Japanese Society of Dialysis Therapy treatment guidelines for secondary hyperparathyroidism.
    Kazama JJ
    Ther Apher Dial; 2007 Oct; 11 Suppl 1():S44-7. PubMed ID: 17976085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [K/DOQI clinical practice guidelines for management of renal osteodystrophy in predialysis patients].
    Okada N; Tsubakihara Y
    Clin Calcium; 2004 May; 14(5):698-706. PubMed ID: 15577030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Challenges in the therapy of secondary hyperparathyroidism.
    Wood C; González EA; Martin KJ
    Ther Apher Dial; 2005 Feb; 9(1):4-8. PubMed ID: 15828898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prevention and treatment of renal osteodystrophy: present and future].
    Fernández E; Craver L
    Nefrologia; 2006; 26 Suppl 3():19-27. PubMed ID: 17469423
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
    Komaba H; Tanaka M; Fukagawa M
    Intern Med; 2008; 47(11):989-94. PubMed ID: 18520108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
    Souqiyyeh MZ; Shaheen FA
    Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):93-101. PubMed ID: 20061700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).
    Isakova T; Nickolas TL; Denburg M; Yarlagadda S; Weiner DE; Gutiérrez OM; Bansal V; Rosas SE; Nigwekar S; Yee J; Kramer H
    Am J Kidney Dis; 2017 Dec; 70(6):737-751. PubMed ID: 28941764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal bone disease.
    Sprague SM
    Curr Opin Endocrinol Diabetes Obes; 2010 Dec; 17(6):535-9. PubMed ID: 21030840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Caring for chronic kidney disease patients: focus on mineral and bone disorders.
    Nguyen TV; Filson J
    Consult Pharm; 2009 Feb; 24(2):146-52. PubMed ID: 19275456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patients with analgetic nephropathy on chronic hemodialysis have a high incidence of severe secondary hyperparathyroidism.
    Pecovnik Balon B; Krpan D
    Clin Nephrol; 1998 Dec; 50(6):347-51. PubMed ID: 9877107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Long-term treatment of secondary hyperparathyroidism in the chronic hemodialysis patient with 1,25-(OH)2D3].
    Giachino G; Giacchino F; Jeantet A; Del Piano A; Garetto A; Pellerey M; Piccoli G
    Minerva Med; 1985 Mar; 76(9-10):407-14. PubMed ID: 2984605
    [No Abstract]   [Full Text] [Related]  

  • 18. Parathyroid hormone variability parameters for identifying high turnover osteodystrophy disease in hemodialysis patients: an observational retrospective cohort study.
    De Paola L; Coppolino G; Bolignano D; Buemi M; Lombardi L
    Ther Apher Dial; 2010 Dec; 14(6):566-71. PubMed ID: 21118364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic kidney disease-mineral and bone disorder (CKD-MBD): a new term for a complex approach.
    Svára F
    J Ren Care; 2009 Mar; 35 Suppl 1():3-6. PubMed ID: 19222724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Parathyroid interventions: final one piece in the management of uremic SHPT patients].
    Uemura K; Kakuta T
    Clin Calcium; 2010 Jul; 20(7):1104-10. PubMed ID: 20585190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.